Literature DB >> 2589442

CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer.

P Sevelda1, M Schemper, J Spona.   

Abstract

Serum CA 125 levels (upper normal value less than 35 U/ml) determined before surgery and 3 months after surgery were evaluated as independent prognostic factors for survival in patients with epithelial ovarian carcinomas. In 163 women preoperative serum levels of CA 125 (p = 0.13) gave no additional information with regard to the relationship of survival prognosis to histologic grade (p = 0.04) and to the diameter of residual tumor mass (p = 0.03). In 132 patients serum CA 125 levels were also determined 3 months after surgery and reflected the effectiveness of the first two cycles of postoperative cytotoxic treatment. At that time CA 125 was the strongest independent prognostic factor for survival (p = 0.0006 Cox model), as compared with histologic grade (p = 0.06), International Federation of Gynecology and Obstetrics stage (p = 0.15), and diameter of residual tumor mass (p = 0.66). Therefore, we concluded that serum CA 125 levels determined 3 months after surgery can identify a high-risk population among patients with epithelial ovarian carcinomas for whom a more aggressive or more intensive treatment might be beneficial.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2589442     DOI: 10.1016/0002-9378(89)90668-6

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  12 in total

1.  The optimal time for surgery in women with serous ovarian cancer.

Authors:  Jocelyn M Stewart; Alicia A Tone; Haiyan Jiang; Marcus Q Bernardini; Sarah Ferguson; Stephane Laframboise; K Joan Murphy; Barry Rosen; Taymaa May
Journal:  Can J Surg       Date:  2016-08       Impact factor: 2.089

2.  Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer.

Authors:  Digant Gupta; Carolyn A Lammersfeld; Pankaj G Vashi; Donald P Braun
Journal:  J Ovarian Res       Date:  2010-10-12       Impact factor: 4.234

Review 3.  CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review.

Authors:  G Colloca; A Venturino; I Governato
Journal:  Clin Transl Oncol       Date:  2015-11-06       Impact factor: 3.405

4.  CA 125 half-life in ovarian cancer: a multivariate survival analysis.

Authors:  C A Yedema; P Kenemans; F Voorhorst; G Bon; C Schijf; L Beex; A Verstraeten; J Hilgers; J Vermorken
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

5.  Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature.

Authors:  Digant Gupta; Christopher G Lis
Journal:  J Ovarian Res       Date:  2009-10-09       Impact factor: 4.234

6.  Prognostic factors in early-stage ovarian cancer.

Authors:  Germana Tognon; Mario Carnazza; Monica Ragnoli; Stefano Calza; Federico Ferrari; Angela Gambino; Valentina Zizioli; Sara Notaro; Benedetta Sostegni; Enrico Sartori
Journal:  Ecancermedicalscience       Date:  2013-06-13

7.  First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer.

Authors:  A Rosen; P Sevelda; M Klein; K Dobianer; C Hruza; K Czerwenka; H Hanak; N Vavra; H Salzer; S Leodolter
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

8.  The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma.

Authors:  J Fisken; R C Leonard; M Stewart; G J Beattie; C Sturgeon; L Aspinall; J E Roulston
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

9.  Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model.

Authors:  M L Hopkins; D Coyle; T Le; M Fung Kee Fung; G Wells
Journal:  Curr Oncol       Date:  2007-10       Impact factor: 3.677

10.  Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer.

Authors:  P Venesmaa; P Lehtovirta; U H Stenman; A Leminen; M Forss; O Ylikorkala
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.